Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable businesses with durable brands, conservative finances, and a price that leaves room for error. Haleon owns recognizable consumer-health brands—Sensodyne, Polident, Parodontax, Biotene, Centrum, Emergen-C, Caltrate—and sells them into repeat-purchase categories. That is a modest moat, but not a wide one. The latest reported quarter, fiscal Q4 2024, produced $2.8B of revenue, $231.0M of net income, and an 8.37% margin. Those are real profits, yet the FairStock return on capital employed is only 5.08% and return on equity is 10.09%, which tells me the business does not earn exceptional returns on the capital it uses. Debt to equity of 0.50 is manageable, the FairStock Altman Z-Score of 2.87 sits in the grey zone, and the FairStock Piotroski F-Score of 4/9 is mediocre. The dividend yield is 2.13%, and the beta of 0.24 suggests a defensive demand profile. Valuation is the sticking point. At the 2026-10-13 close of $9.44, the FairStock P/E is 19.67 and FairStock P/B is 1.91. The FairStock Graham Number is $4.46, giving a margin of safety of -111.66%, meaning the price is far above a conservative asset-and-earnings value. FairStock score is 49/100. No Peter Lynch category is assigned because there are only 0 years of filed results, not the three needed. Growth is not provided in the data, so I cannot underwrite an improving trajectory. I would want a wider discount and evidence that returns on capital and margins are rising before calling this a compelling value.

In plain English: Haleon sells everyday consumer health products such as Sensodyne toothpaste and Centrum vitamins. The business is profitable and carries moderate debt, but its returns on the money it uses are modest and the latest quarter showed an 8.37% net margin. At the 2026-10-13 close of $9.44, the shares look expensive compared with the value suggested by the company's earnings and net assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer